Workshop III: Recommendations for future clinical trials

In the opinion of the participants of the workshop, the following problems should be addressed with high priority: 1st, a clear definition of the 10%–15% of patients who should receive radiotherapy only; 2nd, reduction of toxicity of combined modality approaches for patients in localized stages with...

Full description

Saved in:
Bibliographic Details
Published in:Annals of oncology 1992-09, Vol.3 (suppl-4), p.S101-S104
Main Authors: Pfreundschuh, M., Lathan, B., Löffler, M., Röffer, U., Hasenclever, D., Diehl, V.
Format: Article
Language:English
Subjects:
Antineoplastic agents
Biological and medical sciences
clinical trials
Combined treatments (chemotherapy of immunotherapy associated with an other treatment)
dose intersification
Hodgkin's disease
Medical sciences
overview
Pharmacology. Drug treatments
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In the opinion of the participants of the workshop, the following problems should be addressed with high priority: 1st, a clear definition of the 10%–15% of patients who should receive radiotherapy only; 2nd, reduction of toxicity of combined modality approaches for patients in localized stages with risk factors; and 3rd, definition of a poor-prognosis subgroup of patients in stages IIIB/IV for whom more efficient treatment programs must be developed. Dose intensification in the form of ABMT as the prominent example of high dose intensity should be tested in these patients. If this approach proves its efficacy, the concept of dose intensification could be extended to other patients with advanced disease. Results of recent trials in Hodgkin's disease suggest that the cure rates which increased considerably between 1960 and 1980 have reached a plateau. Further improvements that can be realistically expected will be small and studies to prove such progress need large numbers of patients (‘megatrials’) to avoid ‘false negative’ results. Such megatnals could be performed as large international or even intercontinental trials. To some extent, overviews could sub stitute for megatrials, if sufficient high-quality randomized studies addressing a specific question are available for a meta-analysis. The installation of an international steering committee was recommended, which should stimulate and coordinate world-wide efforts for the solution of the remain ing problems in the treatment of Hodgkin's disease.
ISSN:0923-7534
1569-8041
DOI:10.1093/annonc/3.suppl_4.S101